Volume 21, Number 3—March 2015
Research
Risk Factors for Death from Invasive Pneumococcal Disease, Europe, 2010
Table 5
Stratified analysis of Streptococcus pneumoniae serotype distribution in a study of invasive pneumococcal disease, Europe, 2010*
Age group, y | Survived, no. (%) | Died (%) | RR (95% CI) | p value |
---|---|---|---|---|
<5 | ||||
PCV13-specific | 325 (98.8) | 4 (1.2) | 1 | |
PCV7 | 104 (97.2) | 3 (2.8) | 2.31 (0.35–15.02) | 0.382 |
Non-PCV | 128 (95.5) | 6 (4.5) | 3.68 (1.27–10.69) | 0.017 |
5–64 | ||||
PCV13-specific | 486 (94.4) | 29 (5.6) | 1 | |
PCV7 | 186 (84.9) | 33 (15.1) | 2.68 (1.37–5.23) | 0.004 |
Non-PCV | 451 (92.4) | 37 (7.6) | 1.35 (0.64–2.82) | 0.429 |
>65 | ||||
PCV13-specific | 338 (87.8) | 47 (12.2) | 1 | |
PCV7 | 154 (80.6) | 37 (19.4) | 1.59 (0.90–2.79) | 0.108 |
Non-PCV | 464 (87.2) | 68 (12.8) | 1.05 (0.64–1.72) | 0.856 |
*PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV; RR, relative risk
1Members of the Invasive Pneumococcal Disease Study Group who contributed data are listed at the end of this article.